title: B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients.
abstract: On the basis of responses to surface IgM (sIgM) cross-linking, B cells from 41 patients with B-chronic lymphocytic leukemia were categorized as 15 nonresponders (group I) and 26 responders (group II). The latter cases were subclassified as those seven where proliferation was induced (subgroup IIa) and the remaining 19 in whom apoptosis occurred (subgroup IIa). Signal disruption in group I was confirmed by the absence of Ca2+ mobilization. Activation of PI3K was constitutive in subgroup IIa, but not in subgroup IIb, and that of Akt induced by anti-mu in subgroup IIa, but not in subgroup IIb. Among the MAPK, ERK was more highly activated relative to p38 in subgroup IIa, whereas activation of p38 predominated over that of ERK in subgroup IIb. For subgroup IIb cells, based on tyrosine phosphorylation and translocation into lipid rafts, sIgM signaling was shown to be enhanced by Zap70. The different consequences of signaling through sIgM were associated with biological prognosis indicators. These included high levels of CD38, lack of mutations in the IgVH chain genes, preferential usage of full-length CD79b, and severe clinical stage. Thus, modification of sIgM-induced signaling could be a therapeutic approach.
authors.affiliation: Institut de Synergie des Sciences et de la Santé, Brest University Medical School, Brest, France.
authors.forename: Steven
authors.initials: S
authors.lastname: Nédellec
authors.forename: Yves
authors.initials: Y
authors.lastname: Renaudineau
authors.forename: Anne
authors.initials: A
authors.lastname: Bordron
authors.forename: Christian
authors.initials: C
authors.lastname: Berthou
authors.forename: Nina
authors.initials: N
authors.lastname: Porakishvili
authors.forename: Peter M
authors.initials: PM
authors.lastname: Lydyard
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Pers
authors.forename: Pierre
authors.initials: P
authors.lastname: Youinou
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis; D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D020013:Calcium Signaling; D016022:Case-Control Studies; D049109:Cell Proliferation; D003432:Cross-Linking Reagents; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000378:metabolism*; D066298:In Vitro Techniques; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000145:classification / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism; D010766:Phosphorylation; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011947:Receptors, Antigen, B-Cell / Q000378:metabolism*; D015398:Signal Transduction; D051746:ZAP-70 Protein-Tyrosine Kinase
chemical_list: D003432:Cross-Linking Reagents; D007075:Immunoglobulin M; D011947:Receptors, Antigen, B-Cell; D011505:Protein-Tyrosine Kinases; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human; D020929:Mitogen-Activated Protein Kinase Kinases